BioCentury
ARTICLE | Clinical News

Ad-RTS-hIL-12: Phase I ongoing

July 25, 2016 7:00 AM UTC

Ziopharm reported 3 patient deaths that were unrelated to treatment in an open-label, U.S. Phase I trial evaluating a single intratumoral injection of Ad-RTS-hIL-12 plus escalating doses of daily oral veledimex for 14 days. The first 2 patients died of disease progression and the third died of intracranial hemorrhage. Ziopharm said the intracranial hemorrhage death occurred 15 days after the patient received Ad-RTS-hIL-12 in the study’s third cohort. The trial had enrolled 14 patients through July 13. ...